AI-大規模言語モデル (LLMs) 利用時の欧州『EMA: 欧州医薬品庁/ HMA: 欧州医薬品庁長官』からの指導原則（欧州規制当局内向け）提示と、EMA AI 関連レター発表　のご紹介：–> HiroPharma [NEWS] Vol.6 No.19参照Letter from the (EMA) and the Commissioner of the European Medicines Agency (HMA) regarding the use of AI-LLMs and Guiding Principles (for internal EU Regulatory Authorities). --> Refer to HiroPharma [NEWS] Vol.6 No.19